Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases

[1]  G. Fricker,et al.  Establishment of optimized MDCK cell lines for reliable efflux transport studies. , 2014, Journal of pharmaceutical sciences.

[2]  D. Richardson,et al.  P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration* , 2013, The Journal of Biological Chemistry.

[3]  T. Terasaki,et al.  Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. , 2013, Journal of pharmaceutical sciences.

[4]  T. Terasaki,et al.  A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood–brain barrier in ddY, FVB, and C57BL/6J mice , 2013, Fluids and Barriers of the CNS.

[5]  Michael P. Snyder,et al.  Extensive genetic variation in somatic human tissues , 2012, Proceedings of the National Academy of Sciences.

[6]  G. Hausner,et al.  Homing endonucleases: DNA scissors on a mission. , 2012, Genome.

[7]  J. Dukes,et al.  The MDCK variety pack: choosing the right strain , 2011, BMC Cell Biology.

[8]  T. Terasaki,et al.  Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. , 2011, Journal of pharmaceutical sciences.

[9]  C. Daumas-Duport,et al.  Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. , 2011, Molecular pharmaceutics.

[10]  Takashi Suzuki,et al.  Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.

[11]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[12]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[13]  Y. Sugiyama,et al.  Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates , 2010, Pharmaceutical Research.

[14]  G. Chakravarty,et al.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. , 2009, Biological & pharmaceutical bulletin.

[15]  J. Lupski,et al.  Mechanisms of change in gene copy number , 2009, Nature Reviews Genetics.

[16]  I. Romero,et al.  P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid-β , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  N. Simmons,et al.  Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). , 2008, Biochemical pharmacology.

[18]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[19]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[20]  Jos H Beijnen,et al.  P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan , 2007, Clinical Cancer Research.

[21]  Scott E. Martin,et al.  Applications of RNA interference in mammalian systems. , 2007, Annual review of genomics and human genetics.

[22]  Fyodor D Urnov,et al.  Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases , 2007, Proceedings of the National Academy of Sciences.

[23]  Supratim Choudhuri,et al.  Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters , 2006, International journal of toxicology.

[24]  C. Glaubitz,et al.  Localization of multidrug transporter substrates within model membranes. , 2006, Biochemistry.

[25]  J. Keogh,et al.  Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  M. Bibikova,et al.  Efficient Gene Targeting in Drosophila With Zinc-Finger Nucleases , 2006, Genetics.

[27]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[28]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[29]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[30]  N. Shibata,et al.  In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. , 2005, Biological & pharmaceutical bulletin.

[31]  R. Evers,et al.  Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[32]  David Baltimore,et al.  Chimeric Nucleases Stimulate Gene Targeting in Human Cells , 2003, Science.

[33]  Dana Carroll,et al.  Enhancing Gene Targeting with Designed Zinc Finger Nucleases , 2003, Science.

[34]  T. Friedberg,et al.  Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. , 2002, Biochemical pharmacology.

[35]  L. Faivre,et al.  Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. , 2002, The Journal of pharmacology and experimental therapeutics.

[36]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[37]  A. Aggarwal,et al.  FokI requires two specific DNA sites for cleavage. , 2001, Journal of molecular biology.

[38]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[39]  B. Rothen‐Rutishauser,et al.  Cell cultures as tools in biopharmacy. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  S Chandrasegaran,et al.  Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. , 2000, Nucleic acids research.

[41]  J. Bitinaite,et al.  FokI dimerization is required for DNA cleavage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S Chandrasegaran,et al.  Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A Klug,et al.  Zinc fingers , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  Carol L. Williams,et al.  Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. , 1989, The Journal of biological chemistry.

[45]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Terzi.  Chromosomal variation and the origin of drug-resistant mutants in mammalian cell lines. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Springer Basel.  Gene knockout and knockin by zinc-finger nucleases: current status and perspectives , 2012 .

[48]  M. Pomper,et al.  Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. , 2009, Neoplasia.

[49]  Thomas J. Vidmar,et al.  The Madin Darby Canine Kidney (MDCK) Epithelial Cell Monolayer as a Model Cellular Transport Barrier , 2004, Pharmaceutical Research.

[50]  S Chandrasegaran,et al.  A detailed study of the substrate specificity of a chimeric restriction enzyme. , 1999, Nucleic acids research.

[51]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[52]  J. Silverman.  Multidrug-resistance transporters. , 1999, Pharmaceutical biotechnology.